23 July 2023 in JACCP: Journal of the American College of Clinical Pharmacy
4 July 2026 in The Journal of Medicine Access
AVArturo Villalobos-Madriz
DADadier Arroyo-Monterroza
+5
Introduction: Drug shortages in Latin America represent a widespread and persistent challenge, with a high proportion of hospitals reporting frequent supply disruptions that affect treatment continuity and quality of care. Methodology: A cross-sectional study was conducted using a structured survey applied in 144 hospitals across eight Latin American countries between January and April 2025. A non-probabilistic snowball sampling strategy was used to recruit pharmaceutical professionals and personnel responsible for drug procurement. The questionnaire was developed by the research team and reviewed by a panel of hospital pharmacists to ensure content validity. Data were collected anonymously and are based on self-reported perceptions from professionals representing their institutions. Descriptive analyses and exploratory chi-square tests were performed. Results: 75.0% of the responses came from South America, 20.8% from Mexico and 4.2% from Costa Rica. 75.7% of hospitals reported shortages as a serious problem, with a daily frequency in 30.6% and weekly frequency in 27.8% of cases. The most affected categories were antimicrobial, cardiovascular and oncological. Among the most relevant causes were inefficient procurement processes (84.3% in Argentina; 66.7% in Uruguay and Costa Rica), high prices, supply chain disruptions and global shortages of active ingredients. 53.7% of the hospitals had contingency plans, the presence of which was significantly associated with a lower frequency of shortages (p=0.025). The most commonly used strategies were therapeutic substitution (85–90%), inter-institutional collaboration, and the development of alternative formulations (95.5% in Colombia and 75% in Brazil). Conclusions: Shortage of drugs in the region are a multifactorial phenomenon with a relevant clinical and organizational impact. The implementation of contingency plans and inter-institutional cooperation strategies is associated with improved response capacity, understood as a reduced frequency and better management of shortage events. These findings highlight the need to strengthen contingency planning and promote coordinated regional policies based on the observed variability in causes and mitigation strategies.
30 June 2024 in The Poison
CHCity Of Buenos Aires Central Aeronautical Hospital
City Of Buenos Aires Central Aeronautical Hospital
EHEl Palomar National Poison Center (Cni) - Prof. Alejandro Posadas National Hospital
El Palomar National Poison Center (Cni) - Prof. Alejandro Posadas National Hospital
Background. Toxic epidermal necrolysis (TEN) is a severe systemic disease that affects the skin and mucosa, with a mortality rate above 30%. Pharmaceutical drugs are the main causal agents of this reaction, with most cases being largely associated with phenytoin. There is no generally accepted treatment for TEN. The administration of systemic corticosteroids combined with human intravenous immunoglobulin (IVIG) may be a possible adjuvant therapy. Case presentation. A 72-year-old patient who received phenytoin for four weeks as a prophylactic treatment after undergoing surgery to drain a chronic subdural hematoma developed TEN-compatible symptoms, which prompted treatment with methylprednisolone (1 g/day for 3 days) combined with IVIG (0.5 gr/kg/day for 5 days), with favorable response. Conclusion. Our patient’s response to the combination of corticosteroids and IVIG was favorable. However, due to the nature of this report, the function this combination of drugs has must be further researched.
31 January 2025 in The Poison
Background. One of the most severe complications arising from the IV administration of certain cytostatic drugs is the extravasation into adjacent tissue, which causes local irritation, tissue necrosis, and may even result in amputation of the affected limb. According to the literature, the incidence of extravasations in peripheral intravenous administration ranges from 0.1 to 6%. Clinical cases. Three patients presented suffering from doxorubicin extravasation while undergoing chemotherapy treatment. General measures were applied in all cases, and in one case dimethyl sulfoxide (DMSO) was applied topically as an antidote for 24-48 hrs. All three had favorable responses. Conclusions. Extravasation is a potentially serious complication of doxorubicin infusion. It is key to adhere to safe chemotherapy administration guidelines in order to prevent issues, as well as to continuously train staff.
18 March 2024 in JACCP: Journal of the American College of Clinical Pharmacy